Abiopharma

🔍 Duey Marc (Director)

Company: Aprea Therapeutics, Inc. (APRE)

Report Date: 2026-06-16

Detailed Transactions and Holdings:

• Acquired 3,135 shares of Common Stock (Direct)
  Date: 2026-06-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 259,290.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-16 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 602.00 | Footnotes: F2
• Acquired 12,555 shares of Stock Options (Right to Buy) at $0.7293 per share (Derivative)
  Date: 2026-06-16 | Code: A | Expires: 2036-06-16 | equity_swap_involved: 0 | shares_owned_after: 12,555.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
• F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
• F3: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.